ES2970401T3 - Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza - Google Patents

Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Download PDF

Info

Publication number
ES2970401T3
ES2970401T3 ES13749329T ES13749329T ES2970401T3 ES 2970401 T3 ES2970401 T3 ES 2970401T3 ES 13749329 T ES13749329 T ES 13749329T ES 13749329 T ES13749329 T ES 13749329T ES 2970401 T3 ES2970401 T3 ES 2970401T3
Authority
ES
Spain
Prior art keywords
viral
cells
patient
das181
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13749329T
Other languages
English (en)
Spanish (es)
Inventor
Ron Moss
Tiejun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Application granted granted Critical
Publication of ES2970401T3 publication Critical patent/ES2970401T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES13749329T 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza Active ES2970401T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US201261727627P 2012-11-16 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Publications (1)

Publication Number Publication Date
ES2970401T3 true ES2970401T3 (es) 2024-05-28

Family

ID=48984833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13749329T Active ES2970401T3 (es) 2012-02-17 2013-02-19 Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN104203267A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
KR20170081213A (ko) 2014-11-06 2017-07-11 다나-파버 캔서 인스티튜트 인크. Ezh2 억제제 및 그의 용도
CA2966336A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
EP4065139A1 (en) * 2019-11-25 2022-10-05 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
JP4933046B2 (ja) * 2002-09-06 2012-05-16 フィリップ モーリス ユーエスエー インコーポレイテッド 液体エアロゾル製剤、エアロゾル発生装置およびエアロゾル発生方法
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
KR20150001844A (ko) * 2006-01-24 2015-01-06 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
CA2780193A1 (en) * 2009-11-06 2011-05-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Also Published As

Publication number Publication date
EP2841092C0 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
AU2019226190A1 (en) 2019-09-26
IL273194B2 (en) 2023-02-01
IL234116B (en) 2020-03-31
CN104203267A (zh) 2014-12-10
IL273194B (en) 2022-10-01
EP2841092A1 (en) 2015-03-04
EP2841092A4 (en) 2015-09-16
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
US20170151315A1 (en) 2017-06-01
CN109529026A (zh) 2019-03-29
CA2864746A1 (en) 2013-08-22
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194A (en) 2020-04-30
JP2015508780A (ja) 2015-03-23
AU2017258955A1 (en) 2017-12-14
AU2013221230A1 (en) 2014-10-02
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
US20150132274A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
ES2970401T3 (es) Compuestos y composiciones para uso en un método de tratamiento del virus de parainfluenza
ES2979287T3 (es) Tratamiento de infección respiratoria
ES3055494T3 (en) Treatment of respiratory diseases
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN111467363A (zh) 索非布韦在制备预防和治疗冠状病毒的药物中的应用
CN111420024A (zh) 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
JP2023526200A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の予防または治療のための適合溶質
JP2016535782A (ja) 被験者の気道への酵素の投与のための組成物及び方法
JP7639136B2 (ja) 呼吸器ウイルス感染症の処置又は予防のためのスーパーオキシドジスムターゼ活性を有するポリペプチド及び細胞外小胞の使用
WO2020109621A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
CN108926707A (zh) Pf4的抗rsv应用
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
CN115843267A (zh) 呼吸道病毒感染的治疗
ES2989089T3 (es) Composición farmacéutica para uso en el tratamiento de enfermedad inducida por virus
ES3002532T3 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
WO2024096743A1 (en) Sars-cov-2 binding antibody
WO2022140817A1 (en) Anti-viral proteases and methods of use
CN120829486A (zh) 可有效抗呼吸道rna病毒的多肽类抑制剂及其应用
CN118717729A (zh) 一种干扰素协同外泌体雾化吸入制剂及其制备方法和应用
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
CN115461356A (zh) 用于预防或治疗covid-19的肽